Pharmaceutical Shares of US drug developer Incyte Corp (Nasdaq: INCY) leapt 21% to $32.55 in premarket trading yesterday (August 21) as it announced positive top-line results of the Phase II, randomized, double-blind, placebo-controlled RECAP trial of Jakafi (ruxolitinib), its oral JAK1 and JAK2 inhibitor, in combination with capecitabine (Roche's Xeloda) in patients with recurrent or treatment refractory metastatic pancreatic cancer. 22 August 2013